$12.45 Million in Sales Expected for OptiNose Inc (NASDAQ:OPTN) This Quarter

Share on StockTwits

Wall Street analysts expect OptiNose Inc (NASDAQ:OPTN) to post $12.45 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for OptiNose’s earnings. The highest sales estimate is $12.50 million and the lowest is $12.40 million. OptiNose posted sales of $3.02 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 312.3%. The business is expected to report its next quarterly earnings results on Wednesday, March 4th.

According to Zacks, analysts expect that OptiNose will report full year sales of $35.98 million for the current financial year, with estimates ranging from $35.95 million to $36.00 million. For the next year, analysts anticipate that the company will post sales of $86.75 million, with estimates ranging from $83.10 million to $90.39 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that that provide coverage for OptiNose.

OptiNose (NASDAQ:OPTN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.69). OptiNose had a negative return on equity of 137.60% and a negative net margin of 419.37%. The company had revenue of $12.40 million for the quarter, compared to the consensus estimate of $8.56 million.

A number of brokerages recently weighed in on OPTN. Zacks Investment Research raised OptiNose from a “sell” rating to a “hold” rating in a research report on Saturday, November 16th. ValuEngine downgraded OptiNose from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. OptiNose presently has an average rating of “Buy” and an average target price of $21.50.

In related news, Director Joseph C. Scodari acquired 6,100 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The shares were bought at an average price of $8.64 per share, with a total value of $52,704.00. Also, major shareholder Avista Capital Partners Ii Gp, sold 1,250,000 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $9.17, for a total value of $11,462,500.00. The disclosure for this sale can be found here. 44.30% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in OptiNose by 6.5% in the second quarter. JPMorgan Chase & Co. now owns 2,667,724 shares of the company’s stock valued at $17,073,000 after buying an additional 163,755 shares during the last quarter. BlackRock Inc. raised its stake in OptiNose by 15.9% in the second quarter. BlackRock Inc. now owns 1,918,914 shares of the company’s stock valued at $13,586,000 after buying an additional 263,667 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in OptiNose by 18.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,033,499 shares of the company’s stock valued at $7,234,000 after buying an additional 160,664 shares during the last quarter. Tamarack Advisers LP purchased a new stake in OptiNose in the third quarter valued at about $4,725,000. Finally, Wasatch Advisors Inc. purchased a new stake in OptiNose in the second quarter valued at about $4,746,000. Institutional investors own 68.31% of the company’s stock.

OPTN stock traded down $0.11 during trading on Friday, reaching $9.34. 260,563 shares of the company traded hands, compared to its average volume of 421,316. OptiNose has a 12 month low of $4.44 and a 12 month high of $11.66. The business has a 50 day simple moving average of $9.18 and a 200 day simple moving average of $7.42. The company has a market capitalization of $392.95 million, a price-to-earnings ratio of -3.49 and a beta of 0.75. The company has a debt-to-equity ratio of 1.67, a quick ratio of 4.66 and a current ratio of 4.81.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

See Also: What is quantitative easing?

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.